Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad, India.
Department of Pharmaceutics and Drug Delivery, School of Pharmacy, University of Mississippi, MS, USA; Department Pharmaceutical Sciences, College of Pharmacy, Mercer University, Atlanta, GA 30341, USA.
J Control Release. 2021 Oct 10;338:80-104. doi: 10.1016/j.jconrel.2021.08.011. Epub 2021 Aug 8.
Millions of people die each year from viral infections across the globe. There is an urgent need to overcome the existing gap and pitfalls of the current antiviral therapy which include increased dose and dosing frequency, bioavailability challenges, non-specificity, incidences of resistance and so on. These stumbling blocks could be effectively managed by the advent of nanomedicine. Current review emphasizes over an enhanced understanding of how different lipid, polymer and elemental based nanoformulations could be potentially and precisely used to bridle the said drawbacks in antiviral therapy. The dawn of nanotechnology meeting vaccine delivery, role of RNAi therapeutics in antiviral treatment regimen, various regulatory concerns towards clinical translation of nanomedicine along with current trends and implications including unexplored research avenues for advancing the current drug delivery have been discussed in detail.
每年,全球都有数百万人死于病毒感染。因此,急需克服当前抗病毒疗法的差距和缺陷,这些缺陷包括增加剂量和给药频率、生物利用度挑战、非特异性、耐药性发生率等。纳米医学的出现可以有效地解决这些障碍。目前的综述强调了更深入地了解不同的脂质、聚合物和元素基纳米制剂如何能够潜在地和精确地用于克服抗病毒治疗中的这些缺点。纳米技术与疫苗递送的结合、RNAi 治疗在抗病毒治疗方案中的作用、纳米医学临床转化的各种监管问题以及当前的趋势和影响,包括探索推进当前药物输送的未开发研究途径,都进行了详细的讨论。